NCT07629115 A Long-Term Follow-up Study of the Severe Parkinson's Disease Patients Administered the IPS101A Gene Therapy Product.
| NCT ID | NCT07629115 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Innopeutics Corporation |
| Condition | Parkinson Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 6 participants |
| Start Date | 2026-05-29 |
| Primary Completion | 2031-07-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 6 participants in total. It began in 2026-05-29 with a primary completion date of 2031-07-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the long-term safety of IPS101A and to assess the durability of efficacy in subjects who received IPS101A.
Eligibility Criteria
Inclusion Criteria * Subjects who were enrolled in the IPS101A-10 clinical trial and received IPS101A. * Subjects and/or their legally acceptable representatives who voluntarily provided written informed consent to participate in this long-term follow-up study after being fully informed of the study, and who agreed to comply with all study-related requirements. Exclusion Criteria * Subjects who decline to provide consent for participation in the long-term follow-up study, or for whom follow-up assessments are not feasible due to death or other reasons. * Subjects who, in the judgment of the investigator, are considered unsuitable for participation in the study due to unwillingness or inability to comply with scheduled study visits or other study-related requirements.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07629115 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 80 Years, studying Parkinson Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07629115 currently recruiting?
Yes, NCT07629115 is actively recruiting participants. Contact the research team at clpark@innopeutics.com for enrollment information.
Where is the NCT07629115 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT07629115 clinical trial?
NCT07629115 is sponsored by Innopeutics Corporation. The trial plans to enroll 6 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.